Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
Objective Heart failure (HF) is common with high associated morbidity and mortality. UK National Institute for Health and ...
Given the success of the previous collection, The Complex Phenotype of Diabetic Cardiomyopathy: Clinical Indicators and Novel Treatment Targets, and new advances in the field, we are pleased to ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback